Skip to search formSkip to main contentSkip to account menu

Filgrastim

Known as: R metHuG CSF, R-metHuG-CSF, Filgrastim XM02 
A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating… 
National Institutes of Health

Related topics

Related topics

29 relations
0.8 ML FILGRASTIM-SNDZ 0.6 MG/ML Prefilled Syringe0.8 ML Filgrastim 0.6 MG/ML Prefilled Syringe [Neupogen]1 ML Filgrastim 0.3 MG/ML Injection [Neupogen]CSF3 gene

Broader (3)

Colony-Stimulating FactorsHematologic AgentsRecombinant Proteins

Narrower (3)

NeupogenTopneuterZarxio

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
468 Background: There is only limited data regarding efficacy and safety of FOLFIRINOX in elderly patients with advanced… 
2001
2001
Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose
We have performed univariate and multivariate analysis to determine the factors that affect the kinetics of neutrophil and… 
2000
2000
Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G‐CSF (FLAG)
Abstract: The present study was undertaken to evaluate the efficacy of the association of fludarabine plus Ara‐C and G‐CSF (FLAG… 
1999
1999
A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
Purpose: We administered chemotherapy consisting of a combination of 5-day continuous infusion of cisplatin (20 mg/m2 per day… 
1999
1999
Effect of glycosylation of recombinant human granulocytic colony-stimulating factor on expansion cultures of umbilical cord blood CD34+ cells.
BACKGROUND AND OBJECTIVE Granulocytic colony-stimulating factor (G-CSF) is a cytokine widely used for several purposes such as… 
Review
1998
Review
1998
Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality.
Correspondence: Jens Pedersen-Bjergaard, M.D., Ph.D., The Laboratory for Cancergenetics and Cytogenetics, Section 5702, The… 
1998
1998
Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
PURPOSE To evaluate the impact of granulocyte colony-stimulating factor (G-CSF) priming on peripheral-blood cell counts during… 
1996
1996
Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study.
BACKGROUND: Adjuvant chemotherapy for breast cancer is frequently accompanied by neutropenia requiring dose reduction or… 
1996
1996
Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
BACKGROUND Increased proliferation of endogenous bone marrow progenitor cells in response to the administration of hematopoietic… 
1994
1994
Intensification of the CHOEP Regimen for High-Grade Non- Hodgkin’s Lymphoma by G-CSF: Feasibility of a 14-Day Regimen
Background: The efficacy of chemotherapy protocols for the treatment of high-grade non-Hodgkin’s lymphoma (NHL) has not improved…